INDICATIONS AND USAGE
Tazicef (ceftazidime for injection, USP) is indicated for the treatment of patients with infections caused by susceptible strains of the designated organisms in the following diseases:
1.
Lower Respiratory Tract Infections,
including pneumonia, caused by
Pseudomonas aeruginosa
and other
Pseudomonas
spp.;
Haemophilus influenzae
, including ampicillin-resistant strains;
Klebsiella
spp.;
Enterobacter
spp.;
Proteus mirabilis; Escherichia coli; Serratia
spp.;
Citrobacter
spp.;
Streptococcus pneumoniae
; and
Staphylococcus aureus
(methicillin-susceptible strains).
2.
Skin and Skin-Structure Infections
caused by
Pseudomonas aeruginosa
;
Klebsiella
spp.;
Escherichia coli; Proteus
spp., including
Proteus mirabilis
and indole-positive
Proteus;
Enterobacter
spp.;
Serratia
spp.;
Staphylococcus aureus
(methicillin-susceptible strains); and
Streptococcus pyogenes
(group A beta-hemolytic streptococci).
3.
Urinary Tract Infections,
both complicated and uncomplicated, caused by
Pseudomonas aeruginosa; Enterobacter
spp.;
Proteus
spp., including
Proteus mirabilis
and indole-positive
Proteus; Klebsiella
spp.; and
Escherichia coli
.
4.
Bacterial Septicemia
caused by
Pseudomonas aeruginosa, Klebsiella
spp.,
Haemophilus influenzae, Escherichia coli, Serratia
spp.,
Streptococcus pneumoniae
, and
Staphylococcus aureus
(methicillin-susceptible strains).
5.
Bone and Joint Infections
caused by
Pseudomonas aeruginosa, Klebsiella
spp.,
Enterobacter
spp., and
Staphylococcus aureus
(methicillin-susceptible strains).
6.
Gynecologic Infections,
including endometritis, pelvic cellulitis, and other infections of the female genital tract caused by
Escherichia coli
.
7.
Intra-abdominal Infections,
including peritonitis caused by
Escherichia coli, Klebsiella
spp., and
Staphylococcus aureus
(methicillin-susceptible strains) and polymicrobial infections caused by aerobic and anaerobic organisms and
Bacteroides
spp. (many strains of
Bacteroides fragilis
are resistant).
8.
Central Nervous System Infections,
including meningitis, caused by
Haemophilus influenzae
and
Neisseria meningitidis
. Ceftazidime has also been used successfully in a limited number of cases of meningitis due to
Pseudomonas aeruginosa
and
Streptococcus pneumoniae
.
Tazicef (ceftazidime for injection, USP) may be used alone in cases of confirmed or suspected sepsis. Ceftazidime has been used successfully in clinical trials as empiric therapy in cases where various concomitant therapies with other antibacterial drugs have been used.
Tazicef may also be used concomitantly with other antibacterial drugs, such as aminoglycosides, vancomycin, and clindamycin; in severe and life-threatening infections; and in the immunocompromised patient. When such concomitant treatment is appropriate, prescribing information in the labeling for the other antibacterial drugs should be followed. The dose depends on the severity of the infection and the patient's condition.
To reduce the development of drug-resistant bacteria and maintain the effectiveness of Tazicef (ceftazidime) and other antibacterial drugs, Tazicef (ceftazidime) should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria.
When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.